HK1225632A1 - 雷諾嗪和決奈達隆的藥物組合物 - Google Patents

雷諾嗪和決奈達隆的藥物組合物

Info

Publication number
HK1225632A1
HK1225632A1 HK16113992A HK16113992A HK1225632A1 HK 1225632 A1 HK1225632 A1 HK 1225632A1 HK 16113992 A HK16113992 A HK 16113992A HK 16113992 A HK16113992 A HK 16113992A HK 1225632 A1 HK1225632 A1 HK 1225632A1
Authority
HK
Hong Kong
Prior art keywords
dronedarone
ranolazine
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HK16113992A
Other languages
English (en)
Inventor
Michael Gerber
Neal Huang
Joanna M Koziara
Feng Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1225632A1 publication Critical patent/HK1225632A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16113992A 2013-08-02 2016-12-08 雷諾嗪和決奈達隆的藥物組合物 HK1225632A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361861862P 2013-08-02 2013-08-02

Publications (1)

Publication Number Publication Date
HK1225632A1 true HK1225632A1 (zh) 2017-09-15

Family

ID=51359424

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16113992A HK1225632A1 (zh) 2013-08-02 2016-12-08 雷諾嗪和決奈達隆的藥物組合物

Country Status (18)

Country Link
US (2) US20150037410A1 (zh)
EP (1) EP3027175A1 (zh)
JP (1) JP6141580B2 (zh)
KR (1) KR20160027078A (zh)
CN (1) CN105682642A (zh)
AR (1) AR097202A1 (zh)
AU (1) AU2014296378B2 (zh)
BR (1) BR112016001779A2 (zh)
CA (1) CA2919720A1 (zh)
EA (1) EA201690216A1 (zh)
HK (1) HK1225632A1 (zh)
IL (1) IL243390A0 (zh)
MX (1) MX2016001303A (zh)
NZ (1) NZ715615A (zh)
SG (1) SG11201600104VA (zh)
TW (1) TW201536356A (zh)
UY (1) UY35690A (zh)
WO (1) WO2015017441A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018001582A1 (en) * 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
CN110859843A (zh) * 2019-12-17 2020-03-06 卓和药业集团有限公司 一种治疗动脉硬化合并心绞痛的药物组合物及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083318A (zh) * 2004-11-05 2013-05-08 贝林格尔.英格海姆国际有限公司 包含替米沙坦和氨氯地平的双层片剂
TWI508726B (zh) * 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CN102342907A (zh) * 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone

Also Published As

Publication number Publication date
US20160213569A1 (en) 2016-07-28
EA201690216A1 (ru) 2016-08-31
JP6141580B2 (ja) 2017-06-07
MX2016001303A (es) 2016-04-07
WO2015017441A1 (en) 2015-02-05
AU2014296378B2 (en) 2017-03-30
IL243390A0 (en) 2016-02-29
KR20160027078A (ko) 2016-03-09
EP3027175A1 (en) 2016-06-08
JP2016525554A (ja) 2016-08-25
NZ715615A (en) 2017-06-30
CN105682642A (zh) 2016-06-15
BR112016001779A2 (pt) 2017-08-01
AR097202A1 (es) 2016-02-24
CA2919720A1 (en) 2015-02-05
AU2014296378A1 (en) 2016-01-28
UY35690A (es) 2014-09-30
SG11201600104VA (en) 2016-02-26
US20150037410A1 (en) 2015-02-05
TW201536356A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
IL240290B (en) History of pyridazinone-amide and pharmaceutical preparations containing them
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
SG10201802104QA (en) Pharmaceutical composition of s-ketamine hydrochloride
SG10201912735TA (en) Pharmaceutical composition of s-ketamine hydrochloride
HK1220920A1 (zh) 治療性組合物和其用途
PL2925305T3 (pl) Ulepszone kompozycje farmaceutyczne pimobendanu
PT3205683T (pt) Composições e dispositivos de poli-4-hidroxibutirato
HK1218079A1 (zh) 亞硝酸鹽的藥物製劑及其用途
EP2995308A4 (en) ANTI-HYPOXIC PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
IL241513A0 (en) History of piperazine, their preparation and pharmaceutical preparations containing them
IL240090A0 (en) Preparations containing l-4-chloroquinonerine
HK1219691A1 (zh) 醫藥組成物及其用途
HK1225632A1 (zh) 雷諾嗪和決奈達隆的藥物組合物
IL276838B (en) Oral formulation and suspension of an oncology drug
HK1204916A1 (zh) 淫羊藿苷元的醫藥用途
IL240292A0 (en) History of quinazoline and pharmaceutical preparations containing them
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
HK1222133A1 (zh) 口腔頭孢吡肟組合物及其用途
CL2015003768A1 (es) Procedimientos y composiciones de formulaciones a grano